Knowing that ADAM17 contributes to the invasiveness of tumor cells and that Sp1 binds to its promoter region, it is possible that Sp1 transcription factor may be a new target for anti-invasive therapies [14,23]. This evidence concerns the gene ADAM17 and neoplasm.